FrancophonIA/ELRC3.0 huggingface dataset:
English: Polyvinyl alcohol (partially hydrolysed) Talc (E553b)
Croatian: Film ovojnica poli(vinilni alkohol) (djelomično hidrolizirani)
English: • swelling in the hands, ankles or feet caused by fluid (peripheral oedema)
Croatian: • ako imate anemiju (smanjeni broj crvenih krvnih stanica) • ako Vam zbog tekućine otiču šake, gležnjevi ili stopala (periferni edem)
English: Common side effects:
Croatian: Česte nuspojave:
English: Pale-pink, square, convex, film-coated tablet with “GS” debossed on one side and “K2C” on the other side.
Croatian: Blijedo ružičaste, četvrtaste, konveksne, filmom obložene tablete s utisnutim „GS“ na jednoj i „K2C“ na drugoj strani tablete.
English: Peripheral oedema has been observed with ERAs including ambrisentan.
Croatian: uključujući i ambrisentan, primijećena je pojava perifernih edema.
English: Ambrisentan
Croatian: • mučnina
English: Volibris 5 mg film-coated tablets
Croatian: Volibris 5 mg filmom obložene tablete
English: ANNEX II
Croatian: Dublin 24
English: Aspen Bad Oldesloe GmbH Industriestrasse 32-36 D-23843 Bad Oldesloe Germany or
Croatian: D-23843 Bad Oldesloe
English: → Tell your doctor immediately.
Croatian: Ako primijetite neki od ovih simptoma: → Odmah obavijestite svog liječnika.
English: Ambrisentan has not been studied in a sufficient number of patients to establish the benefit/risk balance in WHO functional class I PAH.
Croatian: 4.4 Posebna upozorenja i mjere opreza pri uporabi Ambrisentan nije ispitivan u dovoljnog broja bolesnika da bi se utvrdio omjer koristi i rizika u bolesnika s PAH-om funkcionalnog razreda
English: An improvement in haemodynamic parameters was observed in patients with PAH after 12 weeks (n=29) in a Phase 2 study (AMB220).
Croatian: (n=29) u fazi 2 ispitivanja (AMB220).
English: → If it is possible you could become pregnant, use a reliable form of birth control (contraception) while you're taking Volibris.
Croatian: Ako postoji mogućnost da zatrudnite koristite pouzdanu metodu zaštite od začeća
English: Most of these decreases were detected during the first 4 weeks of treatment and haemoglobin generally stabilised thereafter.
Croatian: 4 tjedna liječenja, nakon čega je došlo do stabilizacije vrijednosti hemoglobina.
English: Volibris contains lactose, lecithin (soya), Allura red AC Aluminium Lake (E129) and sodium Volibris tablets contain small amounts of a sugar called lactose.
Croatian: Volibris sadrži laktozu, lecitin (iz soje), boju Allura red AC Aluminium Lake (E129) i natrij
English: Pharmacotherapeutic group: Anti-hypertensives, other anti-hypertensives, ATC code: C02KX02
Croatian: FARMAKOLOŠKA SVOJSTVA 5.1 Farmakodinamička svojstva Farmakoterapijska skupina: Antihipertenzivi, ostali antihipertenzivi: ATK oznaka: C02KX02 Mehanizam djelovanja Ambrisentan je peroralno aktivni, antagonist endotelinskih receptora selektivan za endotelin A (ETA) receptor, iz skupine propanoatne kiseline.
English: In the rat, hyperplasia of nasal turbinate bone is a recognised response to nasal inflammation, based on experience with other compounds.
Croatian: promjene kosti nosne školjke su uobičajeni odgovor na upalu nosne sluznice u štakora.
English: Autoimmune hepatitis (see section
Croatian: autoimuni hepatitis (vidjeti dio 4.4) manje često3,8
English: The effects of steady-state ambrisentan (10 mg once daily) on the pharmacokinetics and pharmacodynamics of a single dose of warfarin (25 mg), as measured by PT and INR, were investigated in 20 healthy volunteers.
Croatian: Ispitivan je učinak stanja dinamičke ravnoteže ambrisentana (10 mg jednom dnevno) na farmakokinetiku i farmakodinamiku pojedinačne doze varfarina (25 mg), mjerenu PV-om i INR-om,
English: Patients with WHO FC II and III had a mean baseline 6MWD of 353 metres.
Croatian: Bolesnici s bolešću funkcionalnog razreda II i III prema SZO-u imali su srednju početnu vrijednost
English: • chest pain/discomfort.
Croatian: • bol/nelagoda u prsnom košu
English: Heart failure
Croatian: Oštećenje jetre
English: Gastrointestinal disorders Nausea, vomiting, diarrhoea
Croatian: Mjereni su: smrt, transplantacija pluća, hospitalizacija zbog
English: EU (MA) Number (Invented) name Strength Pharmaceutical Form
Croatian: Broj (EU) odobrenja (Zaštićeno) ime Jačina Farmaceutski oblik
English: Vial (glass) 2 ml (150 mg/ml) 6 (6 x 1) vials + 6 (6 X 1) syringes + 12 (6 X 2) needles (multipack)
Croatian: 2 ml (150 mg/ml) 6 (6 x 1) bočica + 6 (6 x 1) štrcaljki + 12 (6 x 2) igala (višestruko pakiranje)
English: Vial (glass) 2 ml (150 mg/ml) 1 vial + 1 syringe +
Croatian: 2 ml (150 mg/ml) 1 bočica + 1 štrcaljka +
English: Vial (glass) 2 ml (150 mg/ml) 2 (2 X 1) vials + 2 (2 X 1) syringes + 4 (2
Croatian: 2 ml (150 mg/ml) 2 (2 x 1) bočice + 2 (2 x 1) štrcaljke + 4 (2 x 2) igle (višestruko pakiranje)
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration
Croatian: Farmaceutski oblik Put primjene Unutarnje pakiranje
English: (Invented) name Strength Pharmaceutical form
Croatian: (Zaštićeno) ime Doza
English: The full EPAR for Cubicin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Cubicin nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This summary was last updated in 12-2017.
Croatian: Sažetak je posljednji put ažuriran u 12. 2017.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cubicin on 19 January 2006.
Croatian: Europska komisija izdala je odobrenje za stavljanje lijeka Cubicin u promet koje je na snazi u Europskoj uniji od 19. siječnja 2006.
English: Cubicin daptomycin
Croatian: Cubicin daptomicin
English: The duration of treatment with Cubicin depends on the risk of complications and official recommendations.
Croatian: Trajanje liječenja lijekom Cubicin ovisi o riziku od komplikacija i službenim preporukama.
English: This is a summary of the European public assessment report (EPAR) for Cubicin.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) za lijek Cubicin.
English: What measures are being taken to ensure the safe and effective use of Cubicin?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Cubicin?
English: What is Cubicin and what is it used for?
Croatian: Što je Cubicin i za što se koristi?
English: Cubicin is an antibiotic medicine, which is used to treat the following bacterial infections:
Croatian: Cubicin je antibiotik koji se primjenjuje za liječenje sljedećih bakterijskih infekcija:
English: Other information about Cubicin
Croatian: Ostale informacije o lijeku Cubicin
English: Why is Cubicin approved?
Croatian: Zašto je Cubicin odobren?
English: ‘Complicated' means that the infection is difficult to treat, because it has spread to the deep tissues below the skin, treatment with surgery might be needed, or the patient has other conditions that might affect how well treatment works;
Croatian: Kada je infekcija „komplicirana”, znači da ju je teško liječiti jer se proširila na duboka tkiva ispod kože, jer može biti potreban kirurški zahvat ili bolesnik ima druga stanja koja mogu utjecati na uspješnost liječenja,
English: Effectiveness varied between the two studies because of differences in the types of patients and infections being treated.
Croatian: Učinkovitost lijeka u dvama ispitivanjima razlikovala se zbog razlike u tipovima bolesnika i liječenim infekcijama.
English: What are the risks associated with Cubicin?
Croatian: Koji su rizici povezani s lijekom Cubicin?
English: Cubicin is given by infusion lasting 60 minutes in children aged 1 to 6 years and 30 minutes in those aged above 7 years.
Croatian: Lijek Cubicin primjenjuje se infuzijom u trajanju od 60 minuta u djece u dobi između jedne i šest godina te 30 minuta u djece starije od sedam godina.
English: Prescribers should consider official guidance on the use of antibiotics.
Croatian: Liječnici koji propisuju lijek trebaju uzeti u obzir službene smjernice za primjenu antibiotika.
English: It is not intended to provide practical advice on how to use Cubicin.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Cubicin.
English: It can stop the growth of certain types of bacteria by attaching to the membrane surrounding the bacterial cell and upsetting the essential functions that keep the cell alive.
Croatian: Daptomicin može zaustaviti rast određenih vrsta bakterija tako da se veže na membranu koja okružuje stanice bakterije i poremeti osnovne funkcije koje stanicu održavaju aktivnom.
English: • bacteraemia (infection of the blood) caused by S. aureus.
Croatian: • bakterijemije (infekcija krvi) uzrokovane bakterijom S. aureus.
English: The decision to treat this type of infection with Cubicin should be based on the likelihood that the medicine will work against the infection and on advice from an expert;
Croatian: Odluka da se takva vrsta infekcija liječi lijekom Cubicin trebala bi se temeljiti na vjerojatnosti da će lijek djelovati protiv infekcije te nakon savjetovanja sa stručnjakom,
English: In the first two studies involving 1,118 adults with complicated skin and soft tissue infections (mainly wound infections and major abscesses), Cubicin was effective in 67% of patients in one study and in 85% in the other.
Croatian: U prvim dvama ispitivanjima koja su uključivala 1 118 odraslih osoba s kompliciranim infekcijama kože i mekog tkiva (uglavnom infekcijama rana i velikim apscesima), lijek Cubicin bio je učinkovit u 67 % bolesnika u jednom ispitivanju te u 85 % bolesnika u drugom.
English: The third study involved 246 adults with bacteraemia caused by S. aureus, including 35 who also had right-sided infective endocarditis.
Croatian: Treće je ispitivanje obuhvatilo 246 odraslih osoba s bakterijemijom uzrokovanom bakterijom S. aureus, uključujući 35 osoba koje su također imale infektivni endokarditis na desnoj strani srca.
English: The first study in children and adolescents involved 396 patients with complicated skin and soft tissue infections without bacteraemia.
Croatian: Prvo ispitivanje na djeci i adolescentima obuhvatilo je 396 bolesnika s kompliciranim infekcijama kože i mekog tkiva bez bakterijemije.
English: • right-sided infective endocarditis (infection of the lining or the valves of the right side of the heart) caused by the bacterium Staphylococcus aureus (S. aureus) in adults.
Croatian: • infektivnog endokarditisa na desnoj strani srca (infekcija ovojnice ili zalistaka na desnoj strani srca) koji prouzročuje bakterija Staphylococcus aureus (S. aureus) u odraslih osoba.
English: Standard treatments comprised use of antibiotics such as vancomycin, a penicillin (including oxacillin, cloxacillin, flucloxacillin and nafcillin) or a cephalosporin.
Croatian: Standardni oblici liječenja sastojali su se od primjene antibiotika kao što su vankomicin, penicilin (uključujući oksacilin, kloksacilin, flukloksacilin i nafcilin) ili cefalosporin.
English: It is used in adults when the bacteraemia is associated with either of the two infections above, or in adolescents and children from 1 year of age when the bacteraemia is associated with complicated infections of the skin and soft tissue.
Croatian: Lijek se primjenjuje u odraslih osoba kada je bakterijemija povezana s jednom od dviju prethodno navedenih infekcija, ili u adolescenata i djece u dobi od jedne godine i starije kada je bakterijemija povezana s kompliciranim infekcijama kože i mekog tkiva.
English: The most common side effects with Cubicin (seen in between 1 and 10 patients in 100) are infections caused by fungi (moulds and yeasts), urinary tract infections (infection of the structures that carry urine), Candida infection (a fungal infection), anaemia (low red blood cell counts), anxiety, insomnia (difficulty sleeping), dizziness, headache, hypertension (high blood pressure), hypotension (low blood pressure), gastrointestinal and abdominal pain (belly ache), nausea (feeling sick), vomiting, constipation, diarrhoea, flatulence (gas), bloating and distension (feeling as if the tummy is full), rash, pruritus (itching), pain in the limbs (arms or legs), infusion site reactions, pyrexia (fever), asthenia (weakness), abnormal liver tests and raised levels in the blood of an enzyme called CPK (a marker of muscle damage).
Croatian: Najčešće nuspojave lijeka Cubicin (uočene u između 1 i 10 na 100 bolesnika) su infekcije uzrokovane gljivicama (plijesan i kvasac), infekcije urinarnog trakta (infekcija struktura koje prenose urin), infekcija Candidom (gljivična infekcija), anemija (nizak broj crvenih krvnih stanica), tjeskoba, nesanica (poteškoće sa spavanjem), vrtoglavica, glavobolja, hipertenzija (visok krvni tlak), hipotenzija (nizak krvni tlak), gastrointestinalna i abdominalna bol (bol u trbuhu), mučnina (osjećaj slabosti), povraćanje, zatvor, proljev, flatulencija (nakupljanje plinova), nadutost i distenzija (osjećaj punog želuca), osip, pruritus (svrbež), bol u ekstremitetima (rukama ili nogama), reakcije na mjestu primjene infuzije, pireksija (vrućica), astenija (iscrpljenost), abnormalni rezultati jetrenih pretraga i povećane razine enzima CPK u krvi (pokazatelj oštećenja mišića).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cubicin have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Cubicin nalaze se također u sažetku opisa svojstava i u uputi o lijeku.
English: • complicated infections of the skin and soft tissue below the skin in patients from 1 year of age.
Croatian: • kompliciranih infekcija kože i mekog tkiva ispod kože u bolesnika u dobi od jedne godine i starijih.
English: Three main studies in adults and two in children aged between 1 and 17 years found that Cubicin was as effective as standard treatments at curing or improving infection.
Croatian: U trima glavnim ispitivanjima na odraslim osobama i dvama ispitivanjima na djeci u dobi od jedne do 17 godina utvrđeno je da je lijek Cubicin bio jednako djelotvoran u liječenju ili poboljšavanju simptoma infekcija kao standardni oblici liječenja.
English: The active substance in Cubicin, daptomycin, is an antibiotic that belongs to the group ‘lipopeptides'.
Croatian: Djelatna tvar lijeka Cubicin, daptomicin, jest antibiotik koji pripada skupini lipopeptida.
English: The second study in children and adolescents involved 73 patients with bacteraemia caused by S. aureus.
Croatian: Drugo ispitivanje na djeci i adolescentima obuhvatilo je 73 bolesnika s bakterijemijom uzrokovanom bakterijom S. aureus.
English: Higher doses (between 7 and 12 mg/kg once a day) are used if the skin or soft tissue infection is associated with bacteraemia.
Croatian: Više doze (od 7 mg/kg do 12 mg/kg jedanput na dan) primjenjuju se ako je infekcija kože ili mekog tkiva povezana s bakterijemijom.
English: There was insufficient evidence to support the use of Cubicin to treat bacteraemia in patients who did not have either right-sided infective endocarditis or complicated skin and softtissue infections.
Croatian: Nema dovoljno dokaza koji bi poduprli primjenu lijeka Cubicin za liječenje bakterijemije u bolesnika koji nisu imali infektivni endokarditis na desnoj strani srca ili komplicirane infekcije kože i mekog tkiva.
English: Cubicin is given into a vein as an infusion lasting 30 minutes or as an injection lasting 2 minutes.
Croatian: Lijek Cubicin daje se u venu u obliku infuzije u trajanju od 30 minuta ili injekcije koja traje dvije minute.
English: The European Medicines Agency decided that Cubicin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Europska agencija za lijekove zaključila je da koristi lijeka Cubicin nadmašuju s njim povezane rizike te je preporučila davanje odobrenja za stavljanje lijeka u promet.
English: The company that markets Cubicin will provide all doctors who are expected to use Cubicin with a dosage card to ensure the safe use of the medicine.
Croatian: Tvrtka koja stavlja lijek Cubicin u promet dostavit će karticu za doziranje svim liječnicima od kojih se očekuje da će primjenjivati Cubicin kako bi se zajamčila sigurna primjena lijeka.
English: Cubicin is available as a powder that is made up into a solution for injection or infusion (drip) into a vein.
Croatian: Lijek Cubicin dostupan je kao prašak od kojeg se pravi otopina za injekciju ili infuziju (drip) u venu.
English: For more information about treatment with Cubicin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Cubicin pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
English: Serious side effects include hypersensitivity (allergic) reactions, eosinophilic pneumonia (infection of the lungs), drug rash with eosinophilia and systemic symptoms (DRESS, a severe reaction affecting the skin, blood and internal organs), angioedema (rapid swelling of deeper skin tissues) and rhabdomyolysis (breakdown of muscle fibres).
Croatian: Ozbiljne nuspojave uključuju reakcije preosjetljivosti (alergijske reakcije), eozinofilnu pneumoniju (upala pluća), osip prouzročen primjenom lijeka zajedno s eozinofilijom i sistemskim simptomima (sindrom DRESS, ozbiljna reakcija koja zahvaća kožu, krv i unutarnje organe), angioedem (brzo oticanje dubljih kožnih tkiva) i rabdomiolizu (pucanje mišićnih vlakana).
English: What benefits of Cubicin have been shown in studies?
Croatian: Koje su koristi lijeka Cubicin utvrđene u ispitivanjima?
English: For practical information about using Cubicin, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Cubicin bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
English: In the group with endocarditis, treatment was successful in 42% (8 out of 19) of the patients receiving Cubicin compared with 44% (7 out of 16) of the patients receiving standard treatment.
Croatian: U skupini bolesnika s endokarditisom liječenje je bilo uspješno u 42 % (8 od 19) bolesnika koji su primali lijek Cubicin, u usporedbi s 44 % (7 od 16) bolesnika koji su primali standardni oblik liječenja.
English: Treatment was successful in 88% (227 out of 257) of the patients receiving Cubicin compared with 86% (114 out of 132) receiving standard treatment.
Croatian: Liječenje je bilo uspješno u 88 % (227 od 257) bolesnika koji su primali lijek Cubicin, u usporedbi s 86 % (114 od 132) bolesnika koji su primali standardni oblik liječenja.
English: Cubicin contains the active substance daptomycin.
Croatian: Lijek Cubicin sadržava djelatnu tvar daptomicin.
English: How is Cubicin used?
Croatian: Kako se Cubicin koristi?
English: Treatment was successful in 88% (45 out of 51) of the patients receiving Cubicin compared with 77% (17 out of 22) receiving standard treatment.
Croatian: Liječenje je bilo uspješno u 88 % (45 od 51) bolesnika koji su primali lijek Cubicin, u usporedbi sa 77 % (17 od 22) bolesnika koji su primali standardni oblik liječenja.
English: How does Cubicin work?
Croatian: Kako djeluje Cubicin?
English: For endocarditis and for skin or soft tissue infection with bacteraemia, the dose is 6 mg/kg once a day.
Croatian: U slučaju endokarditisa i infekcija kože ili mekog tkiva bakterijemijom doza iznosi 6 mg/kg jedanput na dan.
English: For the full list of side effects and restrictions with Cubicin, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja pri primjeni lijeka Cubicin potražite u uputi o lijeku.
English: In children the dose of Cubicin for skin or soft tissue infection without bacteraemia depends on the child's age and ranges between 5 and 10 mg/kg once a day.
Croatian: U djece s infekcijom kože ili mekog tkiva bez bakterijemije, doza lijeka Cubicin ovisi o dobi djeteta i kreće se u rasponu od 5 mg/kg do 10 mg/kg jedanput na dan.
English: In adults, for skin or soft tissue infections without bacteraemia, Cubicin is given at a dose of 4 mg/kg body weight once a day.
Croatian: U odraslih osoba s infekcijom kože ili mekog tkiva bez bakterijemije primjenjuje se doza lijeka Cubicin od 4 mg/kg tjelesne težine jedanput na dan.
English: This summary was last updated in October 2016.
Croatian: Ovaj sažetak je posljednji put ažuriran u listopadu 2016.
English: It also depends on the use and the way it is given.
Croatian: Ovisi također o primjeni i načinu primjene.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom sedation and analgesia depend on the dose that is used.
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom tjelesnoj težini.
English: The full EPAR for Cepedex can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Cepedex nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: A neurotransmitter is a substance that nerve cells use to communicate with neighbouring cells.
Croatian: Neuroprijenosnik je tvar koju živčane stanice upotrebljavaju za komunikaciju sa susjednim stanicama.
English: Since noradrenaline is involved in maintaining alertness and arousal, reducing its release decreases the level of consciousness, including the sensation of pain.
Croatian: Budući da je noradrenalin uključen u održavanje budnosti i uzbuđenosti, smanjivanjem njegova otpuštanja smanjuje se razina svijesti, uključujući i osjećaj boli.
English: • as premedication before inducing general anaesthesia.
Croatian: • kao premedikacija prije opće anestezije.
English: It works by attaching to receptors known as alpha2-adrenergic receptors and preventing the release of the neurotransmitter noradrenaline from nerve cells in the body.
Croatian: Djeluje na način da prianja na alfa2-adregeničke receptore i sprječava otpuštanje neuroprijenosnika noradrenalina iz živčanih stanica u tijelu.
English: This is a summary of the European public assessment report (EPAR) for Cepedex.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za Cepedex.
English: For dogs the dose depends on their body surface area (calculated using bodyweight) and in cats it is based on bodyweight.
Croatian: U pasa doza ovisi o površini tijela (koja se izračunava na temelju tjelesne težine), a u mačaka se ona temelji na
English: Cepedex is an alpha2-adrenoceptor agonist.
Croatian: Cepedex je agonist alfa2-adrenergičkih receptora.
English: Cepedex dexmedetomidine
Croatian: Cepedex deksmedetomidin
English: Cepedex is used in non-invasive procedures which do not involve breaking the skin or a body cavity.
Croatian: Cepedex se primjenjuje kod neinvazivnih postupaka koji ne uključuju probijanje kože niti tjelesne šupljine.
English: Cepedex can also be used in dogs to provide pain relief and deep sedation when carrying out medical procedures and minor surgery where it is used in combination with butorphanol (a sedative and analgesic).
Croatian: Cepedex se također može koristiti u pasa za ublažavanje boli i duboku sedaciju kod provođenja medicinskih i manjih kirurških zahvata, kada se primjenjuje u kombinaciji s butorfanolom (sedativ i analgetik).
English: The company provided information on the quality and manufacture of Cepedex.
Croatian: Proizvođač je dostavio informacije o kvaliteti i proizvodnji VMP-a Cepedex.
English: • when carrying out mildly to moderately painful procedures and examinations that require the animal to be restrained or sedated and made less sensitive to pain (analgesia).
Croatian: • prilikom provođenja blago do umjereno bolnih zahvata i pregleda kod kojih je potrebno obuzdavanje ili sedacija životinje i smanjenje osjetljivosti na bol (analgezija).